Granulysin and its clinical significance as a biomarker of immune response and NK cell related neoplasms

Figure 6 Serum granulysin. A: Clinical course and trend of serum granulysin in a natural killer (NK) cell type chronic active EB virus infection (CAEBV) patient. For detailed explanation, see GRANULYSIN AS A BIOMARKER, 6: Granulysin in NK cell-related tumors or neoplasm in the text; B: Serum granulysin in patients with NK type and T cell type CAEBV, serum granulysin in patients with NK type (n = 5) and T cell type (n = 4) chronic active EB virus infection. Only in NK type CAEBV, serum granulysin is significantly elevated. Serum granulysin in patients with NK type (n = 5) and T cell type (n = 4) chronic active EB virus infection. Only in NK type CAEBV, serum granulysin is significantly elevated. C: Expression of granulysin and cytokine production in EB virus infected cell lines (SNK1,5,6,10,11: NK cell type, SNT8,15,16,20: γδT cell type). Western blotting was performed by using a monoclonal antibody, RF10 which reacts with 15-kDa but not 9-kDa granulysin. TNF-a and IFN-g in the culture supernatant were assayed by ELISA method. TNE: Tumor necrosis factor; INF: Interferon.